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TRANSVENOUS VERSUS 
TRANSTHORACIC 
CARDIOVERTER- 
DEFIBRILLATOR 
IMPLANTATION 
A comparative analysis of 
morbidity, mortality, and 
survival 
The hypothesis that transvenous implantation of a cardioverter-defibrillator is 
associated with less morbidity than use of a transthoracic approach was investigated 
in a retrospective series of 146 patients. None of these patients had concomitant 
heart procedures, and the preoperative characteristics of the two groups were 
similar. When analyzed by actual technique used (transvenous, 57 patients; 
transthoracic, 89 patients) and by the intention-to-treat method (transvenous, 65 
patients, 8 of whom actually underwent thoracotomy; thoracotomy, 81 patients), 
transvenous implantation was associated with a lower incidence of postoperative 
respiratory complications and atrial fibrillation. Total cardiac mortality and 
freedom from sudden cardiac death in the transvenous and transthoracic groups 
were comparable at 2 years. (J TitORAC CARDIOVASC SURG 1995;109:1066-74) 
David M. Shahian, MD, Warren A. Williamson, MD, Lars G. Svensson, MD, 
Richard S. D'Agostino, MD, David T. Martin, MD, Jonathan R. Ellis, MD, and 
Ferdinand J. Venditti, MD, Burlington, Mass. 
U ntil recently, placement of an implantable car- dioverter-defibrillator (ICD) system required a 
major operative procedure, which was performed 
through a left thoracotomy, sternotomy, or subxi- 
phoid approach. The morbidity and mortality rates 
associated with this procedure, although lower than 
might be expected considering the degree of cardiac 
dysfunction of most ICE) recipients, are still signifi- 
cant. TM Furthermore, some authors have suggested 
that complications of ICD implantation have been 
reported with less rigor than those of other surgical 
procedures. 3 
In an attempt o reduce the perioperative mor- 
bidity and mortality of ICD implantation, as well as 
the associated length of hospitalization and total 
cost, endocardial lead systems have been developed 
that do not require thoracotomy. We present our 
initial experience with 57 such transvenous implants 
performed at our institution (group A) and compare 
them with 89 implantations performed via a sternot- 
omy or thoracotomy (group B). These two groups 
were subjected to a rigorous analysis of perioperative 
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morbidity and mortality in an attempt to assess relative 
safety. This analysis was carried out first with the actual 
technique used (A1 versus B1) and then on an inten- 
tion-to-treat basis (A2 versus B2). 
Material and methods 
The records of all 146 consecutive patients who under- 
went placement of a complete ICD system were reviewed. 
Twenty-seven contemporaneous patients who underwent 
ICD implantation associated with coronary bypass or 
valvular procedures were excluded from analysis because 
such procedures would potentially prejudice th transtho- 
racic group. The preoperative demographic characteris- 
tics, intraoperative electrophysiologic findings, periopera- 
tive morbidity and mortality, and discharge data were 
examined. 
Statistical analysis. Discrete variables were compared 
by Miettinen's modification of Fisher's exact test or the 
Yates corrected X 2 statistic. Continuous variables were 
compared by Student's t test or the Mann-Whitney test. 
Perioperative mortality was defined as any death that 
occurred in the hospital or any death that occurred at 
home within 30 days of ICD implantation unless clearly 
unrelated to the procedure. One patient in the trans- 
venous group died at home of a documented brady- 
arrhythmia 27 days after implantation. This death was 
regarded as unrelated to the operative procedure and was 
listed as a late rather than a perioperative death. How- 
ever, the analysis was also repeated with this patient listed 
with those who had perioperative death. 
Morbidity and mortality data were analyzed in two 
different ways. First, the 57 patients who actually under- 
went transvenous placement (group A1) were compared 
with 89 patients who ultimately underwent transthoracic 
placement (group B1). However, eight patients in group 
B1 had undergone an initial unsuccessful attempt at 
transvenous placement, which could unfairly prejudice the 
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rates of perioperative morbidity and mortality in this 
group (such cases were longer and required more arrhyth- 
mia inductions). Accordingly, the morbidity data were 
reanalyzed with use of an intention-to-treat principle. The 
65 patients who underwent attempted transvenous place- 
ment, even if the procedure failed and a thoracotomy was 
required, were placed in the transvenous group (group 
A2). They were compared with 81 patients (group B2) 
who underwent horacotomy as the planned procedure 
and in whom transvenous placement was not attempted. 
Logistic regression analysis was performed with multi- 
ple preoperative characteristics (age, sex, cause of disease, 
clinical presentation, history of myocardial infarction, 
extent of coronary artery disease, severity of angina, 
cardiac failure, unrevascularized coronary artery disease, 
and operative approach) as independent variables and 
postoperative l ngth of stay less than or equal to 9 days or 
more than 9 days (our median value) as the binary 
dependent variable. This was believed to be the best 
overall indicator of postoperative morbidity. 
Survival analysis was done by the Kaplan-Meier 
method. Total cardiac mortality included all cardiac 
deaths (operative, nonsudden, and sudden) but excluded 
noncardiac deaths. Sudden cardiac deaths included unwit- 
nessed deaths and those that occurred within 1 hour of 
onset of symptoms. Comparison between groups was 
performed with the Tarone-Ware test. 
Surgical techniques 
General. Patients with coronary disease usually under- 
went objective testing for myocardial ischemia. Exceptions 
to this rule included patients whose conditions were too 
clinically unstable or patients whose absence of angina or 
profound left ventricular dysfunction made them unlikely 
candidates for revascularization. Coronary angiography 
was performed when appropriate to determine the need 
for concomitant bypass (a patient requiring such opera- 
tion was excluded from this study). The ejection fraction 
was determined by single-plane right anterior oblique 
contrast ventriculography, two-dimensional echocardiog- 
raphy, or radionuclide ventriculography. All but three of 
the patients underwent extensive preoperative lectro- 
physiologic testing. One of these patients had incessant, 
unprovoked ventricular tachycardia that was pace termi- 
nable, one patient had severe left main coronary artery 
disease, and one patient, after out-of-hospital cardiac 
arrest, did not undergo testing because arrhythmia had 
been noninducible on multiple previous electrophysi- 
ologic studies. 
Perioperative intraaortic balloon counterpulsation was
used for some patients with severe left ventricular dysfunc- 
tion, unrevascularized coronary artery disease, or both con- 
ditions. Patients with perioperative balloon pumps had coun- 
terpulsation discontinued just before induction of each 
episode of arrhythmia, and the device was reactivated im- 
mediately after successful termination of the arrhythmia. 
All patients underwent operation with continuous mon- 
itoring of pulmonary artery and central venous pressures, 
arterial pressure, and, most recently, continuous mixed 
venous oxygen saturation monitoring. Cardioversion and 
defibrillation threshold testing were initiated at 15 joules 
and continued according to a "step protocol." A 10-joule 
buffer between the determined efibrillation threshold 
testing and the maximum output of the ICD generator was 
required. ICD generators were placed in a subrectus 
fascia pocket in the left side of the abdomen. 
After operation, patients received intravenous lidocaine 
(Xylocaine) for 24 hours. The ICD generator was activated 
as soon as possible after operation, usually in the operating 
room. The patients underwent testing in the electrophysi- 
ologic laboratory before discharge from the hospital to 
confirm appropriate ICD function and were subsequently 
followed up in an ICD clinic every 2 months. 
Thoracotomy. Choice of a sternotomy or left thoracot- 
omy was based on several factors. Sternotomy was gener- 
ally restricted to patients who had severe preoperative 
pulmonary dysfunction. A left anterior thoracotomy was 
used for most other patients. Extrapericardial p acement 
of two large patches was used whenever possible with 
multipoint fixation of the patches to the pericardium after 
removal of the overlying fat. Patches were oriented in a 
longitudinal direction. Bipolar screw electrodes were 
placed in a viable portion of myocardium anteroapically 
or high on the left lateral wall. An attempt was made to 
remove chest tubes as early as possible in the postopera- 
tive course, typically on postoperative day 1, to prevent 
contamination of the pleural space. 
Transvenous placement. Pa ients scheduled to receive 
transvenous ICD units were positioned on the operating 
table with a small roll under the left side of the chest to 
provide access for emergency anterior thoracotomy. A 
generator pocket was created in the left side of the 
abdomen, and a short cephalic venous cutdown was 
performed. The defibrillator lead system (Endotak, Car- 
diac Pacemakers, Inc. [CPI], St. Paul, Minn.) consists of 
proximal and distal spring coils for defibrillation. Three 
sizes are available, with 10, 13, or 16 cm spacing between 
the proximal and distal electrodes. The proximal electrode 
was positioned under fluoroscopic ontrol at the right 
atrial-superior vena cava junction, with the tip of the 
electrode placed at the right ventricular apex. It has been 
our subjective impression that the optimal position is 
adjacent to the septum. The Endotak system lead tip also 
has a bipolar rate-sensing and pacing electrode. 
A subcutaneous patch electrode, which is similar to the 
epicardial patch electrode used for transthoracic mplan- 
tation, was used in some patients. Four configurations are 
available using the electrode and patch: these were used in 
randomized fashion as part of a clinical trial during the 
series presented. In configuration 1, the subcutaneous 
patch is the anode and the proximal and distal endocardial 
leads the cathode. In configuration 2, the patch and 
proximal shocking electrode are the anode and the distal 
shocking electrode is the cathode. In configuration 4, the 
distal shocking electrode is the cathode and the subcuta- 
neous patch is the anode. Finally, in configuration 3, the 
proximal shocking electrode is the anode and the distal 
shocking electrode is the cathode. Four additional config- 
urations may be obtained by reversing these polarities. 
Comparable configurations may be obtained with use of a 
subcutaneous array rather than the patch. 
The Endotak system lead was doubly anchored (with 
the sleeves provided) within the cephalic pocket and then 
tunneled subcutaneously to the abdominal pocket, where 
testing was performed. When a patch was used, a subcu- 
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Table I. Demographics 
Group AI:  Group BI: 
transvenous transthoracic 
(n = 57) (n = 89) p Value 
Age in years (median) 68 (23-80) 65 (31-83) 0.4432 
Sex 
Male 46 (80.7%) 72 (80.9%) 
Female 11 (19.3%) 17 (19.1%) 1.0000 
Arrhythmia presentation 
Syncope 18 (31.6%) 31 (34.8%) 
Arrest 23 (40.4%) 34 (38.2%) 0.9203 
Ventricular tachycardia 16 (28.1%) 24 (27.0%) 
Cause* 
Ischemia 47 (82.5%) 68 (76.4%) 
Idiopathic 5 (8.8%) 15 (16.9%) 
Hypertrophic cardiomyopathy 1 (1.8%) 4 (4.5%) 0.2808 
Valvular 3 (5.3%) 2 (2.3%) 
Congenital 1 (1.8%) 0 
Previous myocardial infarction 49 (86.0%) 64 (71.9%) 0.0713 
Previous cardiovascular operation 28 (49.1%) 28 (31.5%) 0.0497 
Extent of coronary artery disease 
Three vessel or left main 22 (38.6%) 26 (29.2%) 0.3189 
Anginal" 
None 45/56 (80.4%) 69/84 (82.1%) 
Mild 7/56 (12.5%) 14/84 (16.7%) 0.1545 
Moderate 4/56 (7.1%) 1/84 (1.2%) 
Severe 0 0 
Thallium testing 
Negative results 15 (26.3%) 21 (23.6%) 
Positive results 9 (15.8%) 11 (12.4%) 0.7350 
Not performed 33 (57.9%) 57 (64.0%) 
Ejection fraction (%, mean) 31.9 -+ 15.3 31.3 -+ 15.2 0.8026 
Left ventricular aneurysm 13 (22.8%) 13 (14.6%) 0.2978 
Unrevascularized coronary artery disease 31 (54.4%) 57 (64.0%) 0.3221 
Preoperative intraaortic balloon pump 6 (10.5%) 26 (29.2%) 0.0114 
*Causes other than ischemic grouped together for statistical analysis. 
]'Only 56 patients ingroup A and 84 patients ingroup B available for analysis. 
taneous pocket was created at the level of the left 
ventricular apex and secured with stitches. This lead was 
also tunneled into theabdominal pocket. 
At the completion of a successful procedure, the Swan- 
Ganz catheter (Baxter Healthcare Corp., Edwards Div., 
Santa Ana, Calif.) was removed under fluoroscopic on- 
trol, with care taken not to dislodge the Endotak system 
lead during withdrawal. Immediate postoperative roent- 
genography provided a baseline reference for lead posi- 
tion. Patients were kept immobile for 24 hours after 
operation and were encouraged to restrict movement of 
the left arm temporarily. Lead position was reconfirmed 
by roentgenography of the chest before the patient was 
discharged from the hospital. 
Results 
Preoperative demographics are reviewed in Table 
I. Eighty percent of patients in both groups were 
men in the seventh decade of life. Seventy percent of 
patients had had a cardiac arrest or syncopal epi- 
sode caused by malignant ventricular arrhythmia, 
and the remainder had had repetitive sustained 
ventricular tachycardia. Ischemic heart disease was 
the cause of the malignant ventricular arrhythmia n
80% of patients in both groups. More than 50% of 
patients had some unrevascularized coronary artery 
disease, although the difference was not significant 
between the two groups. Usually, this unrevascular- 
ized coronary artery disease was an anatomic finding 
only. Of the 88 patients in both groups who had 
some unrevascularized coronary artery disease, 78 
patients (88.6%) were completely free of symptoms 
or had only mild angina nd 61 patients (69.3%) had 
only one- or two-vessel coronary artery disease. The 
remainder of the patients with unrevascularized 
coronary artery disease had poor operative targets 
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or, in one case, eggshell calcification of the ascend- 
ing aorta that precluded safe revascularization. 
Patients with objective or subjective vidence of 
ischemia usually underwent concomitant bypass op- 
eration and were excluded from this study. 
Twenty-six patients had left ventricular aneurysms 
that were not repaired. In all instances, these aneu- 
rysms were either small and asymptomatic (except 
as a possible arrhythmogenic focus) or were associ- 
ated with profound dysfunction of the nonaneurys- 
mal segments. 
The mean ejection fraction in the two groups was 
identical at 31%. Forty-nine percent of group A 
patients had previous cardiovascular operation com- 
pared with 31.5% in group B, which was a statisti- 
cally significant difference (p = 0.0497). In group A, 
10.5 % of patients underwent perioperative intraaor- 
tic balloon counterpulsation support compared with 
29.2% in group B (p = 0.0114). This reflects our 
subjective impression that transvenous insertion is 
better tolerated and that even critically ill patients 
can undergo the procedure without balloon pump 
support. 
The higher incidence of patients in the trans- 
venous group who had a previous cardiovascular 
operation reflected our desire to avoid repeat ho- 
racotomy in those patients. 
No significant difference was detected in defibril- 
lation thresholds between the two groups (trans- 
venous, 14.9 _+ 5.1 joules; transthoracic, 13.3 _+ 5.2 
joules; p = 0.0846). Lead impedance was signifi- 
cantly lower in the thoracotomy group (group A, 
46.8 _+ 7.0 ohms; group B, 37.6 _ 6.1 ohms; p < 
0.0001). 
Seventy-nine (88.8%) of 89 transthoracic proce- 
dures were performed through a limited left thora- 
cotomy and the remainder by way of sternotomy. 
Two extrapericardial patches were used in 85 pa- 
tients (95.5%), and both patches were the large size 
in 73 patients (82.0%). For transvenous placement, 
the most common configuration was "lead only" (42 
patients, 73.7%), with the use of either normal (33 
patients, 57.9%) or reverse (9 patients, 15.8%) 
polarity. 
The median time from operation to hospital 
discharge was 6.0 days in the transvenous group and 
9.0 days in the thoracotomy group (p < 0.0001). 
Calculated on an intent-to-treat basis, the corre- 
sponding values were 6.0 and 10.0 days (p < 0.0001). 
The perioperative rates of morbidity and mortal- 
ity by actual approach used are compared in Table 
II. No deaths occurred in 57 patients in the trans- 
venous group and 2 deaths occurred in the thora- 
cotomy group, although the difference was not sta- 
tistically significant. The mortality data were also 
recalculated including in the group of patients with 
perioperative death the patient who died at home 27 
days after operation (of what was believed to be a 
preexisting bradyarrhythmia). Again, no difference 
in mortality existed between the two groups either 
by the actual (1 of 57 versus 2 of 89, p = 0.8864) or 
intention-to-treat (1 of 65 versus 2 of 81,p = 0.7504) 
methods. No difference was seen in perioperative 
myocardial infarction, the occurrence of ventricular 
arrhythmias, or congestive heart failure after oper- 
ation. More patients in the thoracotomy group 
required postoperative inotropic support (two of 
whom also required intraaortic balloon pumps), but 
the difference was not statistically significant. A 
highly significant increase was noted in the inci- 
dence of postoperative atrial fibrillation in the tho- 
racotomy group: 28% compared with 8.8% for the 
transvenous group (p = 0.0042). 
Pulmonary complications were significantly re- 
duced with the transvenous approach, with a prev- 
alence of atelectasis or lobar collapse of 21.4% in 
the thoracotomy group and 1.8% in the transvenous 
group (p = 0.0007). A higher proportion of 
patients in the transvenous group had no respira- 
tory complications whatsoever (93% versus 66%, 
p = 0.0001). 
These data on morbidity and mortality were then 
recalculated with use of the intention-to-treat prin- 
ciple (Table III). The prevalence of atrial fibrillation 
was still increased nearly threefold in the thoracot- 
omy group compared with that in the transvenous 
group (28.4% versus 10.8%, p = 0.0139). The  
incidence of atelectasis and lobar collapse in the 
transthoracic group was more than twice that of 
the transvenous group, although the p value did not 
attain statistical significance (18.5% versus 7.7%, 
p = 0.0950). Eighty-six percent of patients who 
underwent the transvenous approach ad no com- 
plications whatsoever compared with 69% of the 
transthoracic group (p = 0.0160). 
Logistic regression analysis was performed with 
data from the 140 patients for whom data were 
complete for all variables. Stepwise forward regres- 
sion revealed that only transthoracic operative ap- 
proach correlated with prolonged postoperative 
hospital length of stay (coefficient, 0.8026; coeffi- 
cient/standard error, 3.78; relative risk, 2.22; 95% 
confidence limits 0.46, 10.76). 
Total cardiac survival and freedom from sudden 
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Table II. Complications by actual approach 
Group AI: Group BI: 
transvenous transthoracic 
(n = 57) (n = 89) 
No. % No. % p Value 
Death 
Cardiac complications 
Myocardial infarction 
Inotropic support 
Ventricular tachycardia/ventricular fibrillation 
Atrial fibrillation 
Congestive heart failure 
Heart block 
Tamponade 
No cardiac complications 
Pulmonary complications 
Adult respiratory distress syndrome 
Pneumonia/bronchitis 
Atelectasis/lobar collapse 
Prolonged intubation 
Pulmonary embolism 
No respiratory complications 
Surgical complications 
Revision, same admission 
Hemothorax necessitating chest tube or thoracentesis 
Hemothorax (reoperation) 
Pneumothorax 
Prolonged air leak 
Retroperitoneal hematoma 
Generator seroma, hematoma, erythema (no surgical treatment) 
Generator hematoma, drain 
Generator hematoma, explant 
Generator erosion 
Coronary vessel erosion 
Intraaortic balloon pump vascular injury 
General complications 
Neurologic 
Urinary tract infection 
Urinary retention 
Upper gastrointestinal tract bleeding 
Superior vena cava thrombosis 
Cholecystitis 
Acute tubular necrosis 
Ileus 
0 2 2.3 0.7400 
5 8.8 8 9.0 1.0000 
1 1.8 8 9.0 0.1443 
7 12.3 9 10.1 0.8787 
5 8.8 25 28.1 0.0042 
5 8.8 8 9.0 1.0000 
1 1.8 0 0.7808 
0 1 1.1 1.0000 
38 66.7 53 59.6 0.3945 
0 1 1.1 1.0000 
2 3.5 4 4.5 0.8077 
1 1.8 19 21.4 0.0007 
1 1.8 7 7.9 0.2200 
0 1 1.1 1.0000 
53 93.0 59 66.3 0.0001 
1 1.8 1 1.1 1.0000 
0 4 4.5 0.2688 
0 0 
1 1.8 1 1.1 1.0000 
1 1.8 1 1.1 1.0000 
2 3.5 0 0.3016 
5 8.8 2 2.3 0.1641 
2 3.5 0 0.3016 
0 1 1.1 1.0000 
0 1 1.1 1.0000 
0 1 1.1 1.0000 
0 3 3.4 0.4500 
0 1 1.1 1.0000 
0 6 6.7 0.0959 
1 1.8 3 3.4 0.9816 
1 1.8 1 1.1 1.0000 
0 1 1.1 1.0000 
0 1 1.1 1.0000 
0 2 2.3 0.7400 
2 3.5 1 1.1 0.6743 
cardiac death were compared.  No statistically signif- 
icant differences were seen at 2 years (Figs. 1 and 2). 
Discussion 
The introduct ion of the ICD has greatly dimin- 
ished the risk of sudden cardiac death in pat ients 
with mal ignant ventr icular arrhythmias. In most 
large series, the operat ive mortal i ty rate has ranged 
from 1.5% to 4%. 1-5 Despite some lack of consis- 
tency in the report ing of ICD complications, 3 signif- 
icant per ioperat ive morbidity can occur. 
A nonthoracotomy approach as been developed 
in an attempt to avoid thoracotomy and reduce 
per ioperat ive morbidity, length of hospital stay, and 
cost. Potential  problems with this approach include 
the inabil ity to pass a lead into the appropr iate 
position, inadequate defibri l lation thresholds neces- 
sitating conversion to thoracotomy, lead migration, 
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Table III. Complications by intention-to-treat 
Group A2: Group B2: 
transvenous transthoracic 
(n = 65) (n = 81) 
No, % No. % p Value 
Death 
Cardiac complications 
Myocardial infarction 
Inotropic support 
Ventricular tachycardia/ventricular fibrillation 
Atrial fibrillation 
Congestive heart failure 
Heart block 
Tamponade 
No cardiac complications 
Pulmonary complications 
Adult respiratory distress yndrome 
Pneumonia/bronchitis 
Atelectasis/lobar collapse 
Prolonged intubation 
Pulmonary embolism 
No respiratory complications 
Surgical complications 
Revision, same admission 
Hemothorax necessitating chest ube or thoracentesis 
Hemothorax (reoperation) 
Pneumothorax 
Prolonged air leak 
Retroperitoneal hematoma 
Generator seroma, hematoma, erythema (no surgical treatment) 
Generator hematoma, drain 
Generator hematoma, explant 
Generator erosion 
Coronary vessel erosion 
Intraaortic balloon pump vascular injury 
General complications 
Neurologic 
Urinary tract infection 
Urinary retention 
Upper gastrointestinal tract bleeding 
Superior vena cava thrombosis 
Cholecystitis 
Acute tubular necrosis 
Ileus 
0 2 2.5 0.5759 
8 12.3 5 6.2 0.3169 
3 4.6 6 7.4 0.7357 
8 12.3 8 9.9 0.8357 
7 10.8 23 28.4 0.0139 
7 10.8 6 7.4 0.6731 
1 1.5 0 0.8904 
0 1 1.2 O.5548 
42 64.6 49 60.5 0.6157 
0 1 1.2 0.5548 
2 3,1 4 4.9 0.8992 
5 7,7 15 18.5 0.0950 
2 3,1 6 7.4 0.4431 
0 1 1.2 0.5548 
56 86.2 56 69.1 0.0160 
1 1.5 1 1.2 1.0000 
0 4 4.9 0.1832 
0 0 
1 1.5 1 1.2 1.0000 
1 1.5 1 1.2 1.0000 
2 3.1 0 0.3825 
5 7.7 2 2.5 0.2817 
2 3.1 0 0.3825 
0 1 1.2 0.5548 
0 1 1.2 0.5548 
0 1 1.2 0.5548 
0 3 3.7 0.3267 
0 1 1.2 0.5548 
0 6 7.4 0.0535 
1 1.5 3 3.7 0.7938 
1 1.5 1 1.2 1.0000 
0 1 1.2 0.5548 
0 1 1.2 0.5548 
0 2 2.5 0.5759 
2 3.1 1 1.2 0.8470 
lead fracture (which resulted in abandonment of the 
first-generation endoeardial system), subclavian vein 
thrombosis, pneumothorax, and ventricular free wall 
or ventricular septal perforation. 6
The initial clinical trials of the second-generation 
lead system (CPI Endotak) used in our study began 
in September 1990. Another transvenous device 
manufactured by Medtronic, Inc. (Minneapolis, 
Minn.) has also undergone clinical trials. 
The results of several institutional nd combined 
study groups are now available. Hauser and associ- 
ates 7have reported on 292 epicardial implantations 
performed in comparison with 298 transvenous im- 
plants in a multiinstitutional study. The postopera- 
tive mortality rate was 1.3% in the transvenous 
group and 2.7% in the epicardial group (p value not 
significant), and the frequency of complications 
reported for each group was similar. However, 18% 
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Fig. 1. Comparison of freedom from all cardiac auses of 
death in transvenous and transthoracic groups. No signif- 
icant difference is seen at 2 years. 
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Fig. 2. Comparison of freedom from sudden cardiac 
death in transvenous and transthoracic groups. No signif- 
icant difference is seen at 2 years. 
of patients in the transthoracic group underwent 
concomitant heart operations, cryoablation, or 
pacemaker insertion procedures, none of which 
were performed in the endocardial group. 
Frame and associates 8 reported on 34 patients 
who underwent attempted transvenous lead implan- 
tation with the Medtronic system with an 88.2% 
success rate (30 implants). In their entire series of 
105 patients, including transthoracic procedures, the 
overall operative mortality rate was 3.8%. None of 
the patients who received a transvenous system died 
in the postoperative period, but the perioperative 
morbidity and operative time were increased. 
Saksena and the Medtronic PCD Investigator 
Group 9 reported on a multiinstitutional study of 616 
patients who underwent epicardial ICD placement 
who were compared with 605 patients who had an 
endocardial system. Implantation mortality was 
lower in the endocardial group by either actual or 
intention-to-treat nalysis, although a detailed re- 
view of complications was not reported. Survival 
analysis revealed an advantage for the endocardial 
system at 2 years but only when operative mortality 
was excluded. A major flaw with this study was the 
inclusion of patients who underwent concomitant 
cardiac operation (14.6%) in the epicardial group, 
which probably had a significant adverse impact on 
the perioperative mortality. 
In an initial study by B6cker and associates, z° 
among 107 patients who underwent ransvenous 
ICD placement wit h both CPI and Medtronic de- 
vices, successful implantation was achieved in 99 
patients (92.5%). Although the surgical mortality 
rate for the transvenous group was low (1%), statis- 
tical comparison of perioperative morbidity and 
mortality between transvenous and transthoracic 
groups was not performed. 
Trappe and associates H described their initial 
experience with a CPI Endotak lead system in 47 
patients, with successful implantation i  39 patients 
(83%). The operative mortality rate was high (5%), 
no detailed analysis of morbidity was provided, and 
no comparison was made with a comparable trans- 
thoracic group. 
Bardy and associates a2reported a 95% success 
rate with the Medtronic device in their initial expe- 
rience with 84 patients who underwent attempted 
transvenous lead insertion. They reported an ab- 
sence of postoperative pulmonary complications 
and arrhythmias in the transvenous group. However, 
other significant postoperative complications in- 
cluded eight lead dislodgments (10%), two subcla- 
vian vein occlusions, one pulse generator pocket 
infection, and one lead fracture. 
Two additional abstracts have used the intention- 
to-treat principle to compare transvenous and epi- 
cardial ICD systems. Kleman and associates 13com- 
pared 90 patients in whom the initial implant 
approach was transvenous with 67 comparable 
patients in whom the approach was epicardial. 
Seventy-six (84.4%) of the 90 patients actually re- 
ceived a transvenous system. The surgical mortality 
rate was 2.2% in the transvenous group and 3% in 
the transthoracic group (p value not significant). 
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The prevalence of postoperative morbidity, includ- 
ing supraventricular or ventricular arrhythmias, con- 
gestive heart failure, and pulmonary complications, 
did not differ significantly between the groups, and 
the hospital stay was the same. In a similar inten- 
tion-to-treat analysis, Lehmann and associates 14 
compared 379 patients who were chosen preopera- 
tively to receive atransvenous lead with 401 patients 
who received transthoracic mplants. The trans- 
venous approach was successful in 317 (84%) of 379 
patients. Operative mortality was lower for the 
transvenous group both by intention-to-treat and 
actual implant analysis. An analysis of complications 
was not presented in the abstract, and some patients 
who underwent concomitant heart operations were 
apparently included in the transthoracic group. 
Thus, despite initial trials of a transvenous device 
in multiple centers in the United States and Europe, 
few have rigorously compared the transvenous with 
the transthoracic approach. Such a trial should 
describe perioperative morbidity and mortality both 
in terms of actual and intention-to-treat principles 
and should not be biased against he transthoracic 
group by the inclusion of patients who have concom- 
itant heart operations. We believe that our single 
institution trial, with both transvenous and transtho- 
racic procedures performed by the same group of 
cardiologists and cardiac surgeons, meets these cri- 
teria. Our data demonstrate hat the transvenous 
approach results in lower morbidity than the trans- 
thoracic approach, even when the intention-to-treat 
principle is used. Fewer atrial arrhythmias occur 
because the pericardium is not disturbed, and there 
is a trend toward a lower prevalence of respiratory 
complications because a thoracotomy is not needed. 
Median length of hospital stay after operation is 
shorter with the transvenous approach, and opera- 
tive approach was the only variable in multivariate 
logistic regression analysis that correlated with short 
versus long length of stay. 
Our data concur with those of B6cker and asso- 
ciates, 15 who reported that the prevalence of ven- 
tricular arrhythmias did not differ between the two 
techniques. This finding suggests that ventricular 
arrhythmias arise not from myocardial irritation by 
patch electrodes but possibly from an increase in 
levels of endogenous catecholamines or s me other 
mechanism. 
In our experience, a lead-only configuration was 
used in 73.7% of patients, which is a higher percent- 
age than found in most other series. A reverse 
configuration was used in 9 of these 42 patients 
and may obviate the need for a subcutaneous patch. 
In a nonthoracotomy lead system, it is particularly 
important to ensure satisfactory defibrillation 
thresholds after operation because a rise in chronic: 
defibrillation thresholds over time has been demon- 
strated by Venditti and associates 16 and Hsia, 
Flores, and Marchlinski. 17 
Only one of our patients had lead migration that 
necessitated revision during the same hospitaliza- 
tion. This low incidence attests to the importance 
and efficacy of the maneuvers discussed in the 
surgical technique section. 
Our survival analysis suggests that, at least during 
short-term follow-up, no difference xists between 
the transvenous and transthoracic approaches. 
In conclusion, transvenous ICD implantation may 
be achieved with a high rate of success and lower 
morbidity than that for the transthoracic procedure, 
and survival is comparable. Subsequent develop- 
ments in ICD technology, including biphasic shocks 
and the use of multielectrode subcutaneous arrays, 
should further increase the likelihood of successful 
transvenous implantation and reduce the need for 
thoracotomy. 
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